May 1, 2009 – Solvay Pharmaceuticals, Inc. today announced that the U.S. FDA approved CREON (pancrelipase) Delayed-Release Capsules for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions. CREON is the first and only pancreatic enzyme product (PEP) to receive FDA approval under new guidelines for the class.
The details can be read here.
No comments:
Post a Comment